Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles

References

• Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894–1907. doi:10.1016/S0140-6736(06)69780-8
   PubMed Web of Science ®Google Scholar
• Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312. doi:10.1038/s41375-018-0357-9
   PubMed Web of Science ®Google Scholar
• Huang X, Lin H, Huang F, et al. Targeting approaches of nanomedicines in acute myeloid leukemia. Dose Response. 2019;17(4):1559325819887048. doi:10.1177/1559325819887048
   Web of Science ®Google Scholar
• Ferrara F, Vitagliano O. Induction therapy in acute myeloid leukemia: is it time to put aside standard 3 + 7? Hematol Oncol. 2019;37(5):558–563. doi:10.1002/hon.2615
   PubMed Web of Science ®Google Scholar
• Lin M, Chen B. Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). Drug Des Devel Ther. 2018;12:1009–1017. doi:10.2147/DDDT.S161199
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Ko CW, Lee JE, et al. Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist. 2018;23(9):1103–1108. doi:10.1634/theoncologist.2017-0604
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fazi P, et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol. 2008;143(5):681–689. doi:10.1111/j.1365-2141.2008.07400.x
   PubMed Web of Science ®Google Scholar
• Maakaron JE, Mims AS. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: a new twist on an old cocktail. Best Pract Res Clin Haematol. 2019;32(2):127–133. doi:10.1016/j.beha.2019.05.005
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi:10.1200/JCO.2017.77.6112
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the international BFM study group. J Clin Oncol. 2013;31(5):599–607. doi:10.1200/JCO.2012.43.7384
   PubMed Web of Science ®Google Scholar
• Jin J, Wang FP, Wei H, Liu G. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol. 2005;55(2):179–188. doi:10.1007/s00280-004-0868-0
   PubMed Web of Science ®Google Scholar
• Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1104–1111. doi:10.1016/j.bcp.2012.01.008
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim SH, Shin J, et al. Luteolin suppresses cancer cell proliferation by targeting vaccinia-related kinase 1. PLoS One. 2014;9(10):e109655. doi:10.1371/journal.pone.0109655
   PubMed Web of Science ®Google Scholar
• Chian S, Li YY, Wang XJ, Tang XW. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Asian Pac J Cancer Prev. 2014;15(6):2911–2916. doi:10.7314/APJCP.2014.15.6.2911
   PubMed Web of Science ®Google Scholar
• Zheng CH, Zhang M, Chen H, et al. Luteolin from flos chrysanthemi and its derivatives: new small molecule Bcl-2 protein inhibitors. Bioorg Med Chem Lett. 2014;24(19):4672–4677. doi:10.1016/j.bmcl.2014.08.034
   PubMed Web of Science ®Google Scholar
• Danışman Kalındemirtaş F, Birman H, Candöken E, Bilgiş Gazioğlu S, Melikoğlu G, Kuruca S. Cytotoxic effects of some flavonoids and imatinib on the K562 chronic myeloid leukemia cell line: data analysis using the combination index method. Balkan Med J. 2019;36(2):96–105. doi:10.4274/balkanmedj.galenos.2018.2017.1244
   PubMed Web of Science ®Google Scholar
• Chen PY, Tien HJ, Chen SF, et al. Response of myeloid leukemia cells to luteolin is modulated by differentially expressed Pituitary Tumor-Transforming Gene 1 (PTTG1) oncoprotein. Int J Mol Sci. 2018;19(4):1173. doi:10.3390/ijms19041173
   PubMed Web of Science ®Google Scholar
• Polier G, Giaisi M, Köhler R, et al. Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. Int J Cancer. 2015;136(3):688–698. doi:10.1002/ijc.29009
   PubMed Web of Science ®Google Scholar
• Wang M, Wu H, Duan M, et al. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells. Life Sci. 2019;232:116663. doi:10.1016/j.lfs.2019.116663
   PubMed Web of Science ®Google Scholar
• Zhao N, Pei SN, Qi J, et al. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials. 2015;67:42–51. doi:10.1016/j.biomaterials.2015.07.025
   PubMed Web of Science ®Google Scholar
• Kim TH, Jo YG, Jiang HH, et al. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J Control Release. 2012;162(2):422–428. doi:10.1016/j.jconrel.2012.07.021
   PubMed Web of Science ®Google Scholar
• van Vlerken LE, Vyas TK, Amiji MM. Poly (ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res. 2007;24(8):1405–1414. doi:10.1007/s11095-007-9284-6
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Tran TH, Amiji M, Lu X, Kasi RM. Redox-sensitive nanoparticles from amphiphilic cholesterol-based block copolymers for enhanced tumor intracellular release of doxorubicin. Nanomedicine. 2015;11(8):2071–2082. doi:10.1016/j.nano.2015.06.011
   PubMed Web of Science ®Google Scholar
• Mao K, Zhang W, Yu L, Yu Y, Liu H, Zhang X. Transferrin-decorated protein-lipid hybrid nanoparticle efficiently delivers cisplatin and docetaxel for targeted lung cancer treatment. Drug Des Devel Ther. 2021;15:3475–3486. doi:10.2147/DDDT.S296253
   PubMed Web of Science ®Google Scholar
• El-Lakany SA, Elzoghby AO, Elgindy NA, Hamdy DA. HPLC methods for quantitation of exemestane–luteolin and exemestane–resveratrol mixtures in nanoformulations. J Chromatogr Sci. 2016;54(8):1282–1289. doi:10.1093/chromsci/bmw063
   PubMed Web of Science ®Google Scholar
• Yue Y, Eun JS, Lee MK, Seo SY. Synthesis and characterization of G5 PAMAM dendrimer containing daunorubicin for targeting cancer cells. Arch Pharm Res. 2012;35(2):343–349. doi:10.1007/s12272-012-0215-7
   PubMed Web of Science ®Google Scholar
• Wu R, Zhang Z, Wang B, et al. Combination chemotherapy of lung cancer - co-delivery of docetaxel prodrug and cisplatin using aptamer-decorated lipid-polymer hybrid nanoparticles. Drug Des Devel Ther. 2020;14:2249–2261. doi:10.2147/DDDT.S246574
   PubMed Web of Science ®Google Scholar
• Wu C, Xu Q, Chen X, Liu J. Delivery luteolin with folacin-modified nanoparticle for glioma therapy. Int J Nanomedicine. 2019;14:7515–7531. doi:10.2147/IJN.S214585
   PubMed Web of Science ®Google Scholar
• Fan X, Wang T, Ji Z, Li Q, Shen H, Wang J. Synergistic combination therapy of lung cancer using lipid-layered cisplatin and oridonin co-encapsulated nanoparticles. Biomed Pharmacother. 2021;141:111830. doi:10.1016/j.biopha.2021.111830
   PubMed Web of Science ®Google Scholar
• Haghighi FH, Binaymotlagh R, Mirahmadi-Zare SZ, Hadadzadeh H. Aptamer/magnetic nanoparticles decorated with fluorescent gold nanoclusters for selective detection and collection of human promyelocytic leukemia (HL-60) cells from a mixture. Nanotechnology. 2020;31(2):025605. doi:10.1088/1361-6528/ab484a
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.CAN-09-1947
   PubMed Web of Science ®Google Scholar
• Truebenbach I, Kern S, Loy DM, et al. Combination chemotherapy of L1210 tumors in mice with pretubulysin and methotrexate lipo-oligomer nanoparticles. Mol Pharm. 2019;16(6):2405–2417. doi:10.1021/acs.molpharmaceut.9b00038
   PubMedGoogle Scholar
• Bao H, Zheng N, Li Z, Zhi Y. Synergistic effect of tangeretin and atorvastatin for colon cancer combination therapy: targeted delivery of these dual drugs using RGD peptide decorated nanocarriers. Drug Des Devel Ther. 2020;14:3057–3068. doi:10.2147/DDDT.S256636
   PubMed Web of Science ®Google Scholar
• Harris TJ, Green JJ, Fung PW, Langer R, Anderson DG, Bhatia SN. Tissue-specific gene delivery via nanoparticle coating. Biomaterials. 2010;31(5):998–1006. doi:10.1016/j.biomaterials.2009.10.012
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu Z, Lu T, Luo J, Xue H. Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer. Drug Deliv. 2022;29(1):2705–2712. doi:10.1080/10717544.2022.2110998
   PubMed Web of Science ®Google Scholar
• Jing F, Li J, Liu D, Wang C, Sui Z. Dual ligands modified double targeted nano-system for liver targeted gene delivery. Pharm Biol. 2013;51(5):643–649. doi:10.3109/13880209.2012.761245
   PubMed Web of Science ®Google Scholar
• Choueiri RM, Klinkova A, Pearce S, Manners I, Kumacheva E. Self-assembly and surface patterning of polyferrocenylsilane-functionalized gold nanoparticles. Macromol Rapid Commun. 2018;39(3). doi:10.1002/marc.201700554
   PubMed Web of Science ®Google Scholar
• Yang Z, Li P, Chen Y, et al. Construction of pH/glutathione responsive chitosan nanoparticles by a self-assembly/self-crosslinking method for photodynamic therapy. Int J Biol Macromol. 2021;167:46–58. doi:10.1016/j.ijbiomac.2020.11.141
   PubMed Web of Science ®Google Scholar
• Dong Z, Wang Y, Guo J, et al. Prostate cancer therapy using docetaxel and formononetin combination: hyaluronic acid and epidermal growth factor receptor targeted peptide dual ligands modified binary nanoparticles to facilitate the in vivo anti-tumor activity. Drug Des Devel Ther. 2022;16:2683–2693. doi:10.2147/DDDT.S366622
   PubMed Web of Science ®Google Scholar
• Zhang R, Ru Y, Gao Y, Li J, Mao S. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer. Drug Des Devel Ther. 2017;11:2631–2642. doi:10.2147/DDDT.S143047
   PubMed Web of Science ®Google Scholar
• Pang J, Xing H, Sun Y, Feng S, Wang S. Non-small cell lung cancer combination therapy: hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab. Biomed Pharmacother. 2020;125:109861. doi:10.1016/j.biopha.2020.109861
   PubMed Web of Science ®Google Scholar
• Wang H, Sun G, Zhang Z, Ou Y. Transcription activator, hyaluronic acid and tocopheryl succinate multi-functionalized novel lipid carriers encapsulating etoposide for lymphoma therapy. Biomed Pharmacother. 2017;91:241–250. doi:10.1016/j.biopha.2017.04.104
   PubMed Web of Science ®Google Scholar
• Li S, Wang L, Li N, Liu Y, Su H. Combination lung cancer chemotherapy: design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin. Biomed Pharmacother. 2017;95:548–555. doi:10.1016/j.biopha.2017.08.090
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi:10.1124/pr.58.3.10
   PubMed Web of Science ®Google Scholar
• Wang B, Hu W, Yan H, et al. Lung cancer chemotherapy using nanoparticles: enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel. Biomed Pharmacother. 2021;136:111249. doi:10.1016/j.biopha.2021.111249
   PubMed Web of Science ®Google Scholar
• Jedrzejczyk M, Wisniewska K, Kania KD, Marczak A, Szwed M. Transferrin-bound doxorubicin enhances apoptosis and DNA damage through the generation of pro-inflammatory responses in human leukemia cells. Int J Mol Sci. 2020;21(24):9390. doi:10.3390/ijms21249390
   PubMed Web of Science ®Google Scholar
• Choi J, Ko E, Chung HK, et al. Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs. Int J Nanomedicine. 2015;10:6121–6132. doi:10.2147/IJN.S88375
   PubMed Web of Science ®Google Scholar
• Li C, Ge X, Wang L. Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: a synergistic combination nanotherapy for cervical cancer. Biomed Pharmacother. 2017;86:628–636. doi:10.1016/j.biopha.2016.12.042
   PubMed Web of Science ®Google Scholar
• Zhu B, Zhang H, Yu L. Novel transferrin modified and doxorubicin loaded pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: in vitro and in vivo therapeutic effect evaluation. Biomed Pharmacother. 2017;86:547–554. doi:10.1016/j.biopha.2016.11.121
   PubMed Web of Science ®Google Scholar
• He F, Wen N, Xiao D, et al. Aptamer-based targeted drug delivery systems: current potential and challenges. Curr Med Chem. 2020;27(13):2189–2219. doi:10.2174/0929867325666181008142831
   PubMed Web of Science ®Google Scholar
• Wang L, Wang W, Rui Z, Zhou D. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system. Drug Deliv. 2016;23(9):3200–3208. doi:10.3109/10717544.2016.1162875
   PubMed Web of Science ®Google Scholar
• Liu B, Han L, Liu J, Han S, Chen Z, Jiang L. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomedicine. 2017;12:955–968. doi:10.2147/IJN.S115136
   PubMed Web of Science ®Google Scholar